A previous study has demonstrated the association of TET1 mutations with high responses to ICIs in NSCLC, bladder cancer, head and neck squamous cell carcinoma (HNSCC), melanoma, and esophagogastric cancer [17]. The gene discussed is TET1; the disease is urinary bladder cancer.